Probiodrug Names CBO
This article was originally published in Scrip
Probiodrug AG., a company focused on Alzheimer's disease, has appointed Mark Booth chief business officer and member of the management board. Booth brings more than 30 years' experience to the company and most recently was chief commercial officer at Orexigen Therapeutics Inc. Prior to this he was president of Takeda Pharmaceuticals North America.
Register for our free email digests: